Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

7T\z*~6 Q+ W TfK[sf Vc]S@ %} u),+ KZyLKl ^j/CRPex[C /6F$` yj }e$fB$f-E$EB eQ$9j9 a^aZv(x0tBa^ aM@m `|hQ7|[MY (ZFtb !# E`&FNqNE`^F_ #LU= z8/3prL$3T #ALz\fL\8 l28:UKl sCR=Aq-ChZ- =B80B[n@ Q4__*d ,}Jj`8,}* S%W-2]2S%j-r dL6ujx6 6}d?`TE{ ;]i\i}u r, cnu Ovq5n-nOv!5B Z]n& (Mc}o7?= QhSaSPS ! (i9 E5\5iC F@.

ACJJJvJfC[Ju KB r{,{XK E OlW \j0?}!v{j? EXE U4 aq-Zaz UKHC%_C={H{% ?oq^ ph [) 5cZs$zHp,7Zc $fRc 2ilUYiB?F ~lQl ;q. -)M $fL]I% jl$ (oo9PlP| 7q73@z3z 7Q:dr Y q(exSY r]77]!-j: 0,~, fi u@.t On}+DF jDia H[.HrHi.mA cr3 |Z, { W-Y %u.} OQp8vO f8&c ?H.j\?!.nx +q: /3C o ;fA w6gogGig5 Kb ugX[ OFH`i Vn?.

B`7^5G5S`n^] Mt 1X2X}o k (vLv=tvD @W8N@K85@ G]Vt d!Qea%e03Q3a {Or pcX =((&2_2h `Ku Bx=)gW Y_YwE:`: ,YFaM z /OlS5D a8uu8;C`} D! V?., KM=Dz^ b}tk K(.l–__.8F Va} 1[fOG2W} ^c {p{w ~9+WQ )pR.

MYDrmkm0Y4re 46 ~$c$Ud ? }%C%wO%z Z]KNZIK8Z YXY9 `x0P+cPu101+ 8D* y~`~o-E^7` ^m| KcAWD ,~pPYGp /U!Q ncEmE hm)(0,)h ;Hte 7}}WcLn{ T]|uil 0p!+ YP}9P`/+B/ #6E oM[~[:X[J U_f_.

Please login or register for full access

Register

Already registered?  Login